不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析

Abstract
Figure/Table
References (24)
Related Citation (13)

Download: PDF (1060 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical effect of malignant pleural effusion in non-small cell lung cancer treated with different doses of Recombinant Human Endostatin Injection and Cisplatin thoracic perfusion. Methods Clinical data of 76 patients with malignant pleural effusion in non-small cell lung cancer in Baoji Central Hospital of Shaanxi Province from February 2012 to January 2017 were retrospectively analyzed. All patients were divided into treatment group Ⅰ (36 cases) and treatment group Ⅱ (40 cases) according to different treatment methods. The lung function, blood gas analysis and quality of life scores were observed before and after treatment in both groups. The short-term efficacy and toxicity between two groups were observed. Results FEV1, FEV1%Pred, FEV1/FVC, PaO2, physical function, mental function, social function, common symptoms scores of treatment group Ⅰ and treatment group Ⅱ after treatment were higher than before treatment, PaCO2 was lower than before treatment, the differences were statistically significant (P < 0.05). FEV1, FEV1%Pred, FEV1/FVC, PaO2, physical function, mental function, social function, common symptoms scores of treatment group Ⅱ after treatment were higher than those of treatment group Ⅰ, PaCO2 was lower than treatment group Ⅰ, the differences were statistically significant (P < 0.05). The remission rate of short-term effect in treatment group Ⅱ was higher than that in treatment group Ⅰ, the difference was statistically significant (P < 0.05). There were no significant differences in incidence rate of gastrointestinal symptoms, myelosuppression, fever, chest pain and cardiac toxicity between two groups (P > 0.05). Conclusion Lung function and life quality of Recombinant Human Endostatin Injection (60 mg) and Cisplatin perfusion in the treatment of non-small cell lung cancer patients with malignant pleural effusion are well recovered. The effect is obvious, it is worthy of clinical promotion and application.

Key words： Different doses Recombinant Human Endostatin Injection Cisplatin Thoracic perfusion Non-small cell lung cancer Malignant pleural effusion

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hua ZHAO Ya′ning▲ ZHANG Bin

Cite this article:

WANG Hua ZHAO Ya′ning▲ ZHANG Bin. Clinical analysis of malignant pleural effusion in non-small cell lung cancer treated with different doses of Recombinant Human Endostatin Injection and Cisplatin thoracic perfusion[J]. 中国医药导报, 2017, 14(23): 88-91,106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I23/88

[1] 陈大朝，纪荣佳，管凯，等.顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床疗效及其对VEGF的影响[J].检验医学与临床，2015，12（20）：3044-3045.
[2] Shinkaruk S，Bayle M，Lain G，et al. Vascular endothelial cell growth factor （VEGF），an emerging target for cancer chemotherapy [J]. Curr Med Chem Anticancer Agents，2003， 3（2）：95-117.
[3] 涂建仁，黄淑娟，王美鑑，等.重组人血管内皮抑制素联合顺铂胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床疗效[J].实用癌症杂志，2014，29（12）：1592-1594.
[4] Fang F，Chen P，Wu X，et al. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion [J]. J Cancer Ｒes Clin Oncol，2009，135（5）：1149-1157.
[5] 志真，石建华，侯森，等.恩度联合顺铂局部治疗非小细胞肺癌合并恶性胸腔积液的疗效及对VEGF、HIF-1α的影响[J].实用癌症杂志，2014，29（7）：855-857.
[6] Fang F，Chen P，Wu X，et al. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion [J]. J Cancer Res Clin Oncol，2009，135（9）：1149-1157.
[7] 万果，石磊，邢时云，等.恩度联合顺铂腔内灌注治疗非小细胞肺癌合并恶性胸腔积液25例疗效观察[J].贵州医药，2014，38（6）：509-510.
[8] Ma XQ，Yao YW，Yuan DM，et al. Recombinant human endostatin endostar suppresses angiogenesis and lym phangiogenesis of malignant pleural effusion in mice [J]. PLoS One，2012，7（12）：e53449.
[9] 邹华，单锦露，李梦侠，等.438例肺癌恶性胸腔积液的诊治及预后因素分析[J].重庆医学，2015，25（27）：3794-3797，3802.
[10] Bao Y，Peng F，Zhou QC，et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage Ⅲ non-small-cell lung cancer [J]. Radiother Oncol，2015，114（2）：161-166.
[11] 唐博，谭群友，王如文，等.胸腔内注射重组人p53腺病毒治疗肺癌恶性胸腔积液的临床研究[J].局解手术学杂志，2015，21（2）：192-194.
[12] Sioris T，Sihvo E，Salo J，et al. Long-term indwelling pleural catheter （Pleurx） for malignant pleural effusion unsuitable for talcpleurodesis [J]. Eur J Surg Oncol，2009，35（5）：546-551.
[13] 王纯，杨燕峰，费晓东，等.重组改构人肿瘤坏死因子胸腔灌注法治疗老年肺癌恶性胸腔积液的疗效观察[J].癌症进展，2016，14（1）：84-86.
[14] 钱形邦，梁洪雁，梁肇和，等.重组人血管内皮抑制素联合顺铂和博来霉素治疗肺癌恶性胸腔积液的效果比较[J].中国当代医药，2015，22（20）：118-120，123.
[15] 胡涛，陈晓林，黄玉民，等.重组改构人肿瘤坏死因子联合顺铂治疗肺癌恶性胸腔积液的效果[J].中国当代医药，2016，23（2）：47-49.
[16] 邹俊韬，胡珍珍，陈颖兰.顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床效果和不良反应观察[J].中国当代医药，2016，23（24）：22-24.
[17] 胡永华，范宇飞，李定纲.顺铂序贯榄香烯联合热疗治疗恶性胸腔积液的效果分析[J].中国当代医药，2016， 23（31）：74-76.
[18] Winkler F，Kozin SV，Tong RT，et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor respcrse to radiation：role of oxygenation，angiopoietin-1，and matrix metallo proteinases [J]. Cancer Cell，2004，6（6）：553-563.
[19] 陈大朝，纪荣佳，管凯，等.顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床疗效及其对VEGF的影响[J].检验医学与临床，2015，12（20）：3044-3045，3047.
[21] Tong RT，Boucher Y，Kozin SV，et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors [J]. Cancer Res，2004，64（11）：3731-3736.
[21] 冯志红，聂秀红.肺癌恶性胸腔积液患者胸腔内注射治疗的临床研究[J].实用癌症杂志，2015，30（11）：1643-1645，1655.
[22] Jain RK，Duda DG，Clark JW，et al. Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pract Oncol，2006，3（1）：24-40.
[23] Fang F，Chen P，Wu X，et al. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion [J]. J Cancer Res Clin Oncol，2009，135（9）：1149-1157.
[24] Hirayama N，Tabatachihar U，Tabata R，et al. Pleuraleffusion VEGF levels as a prognostic factor of malignant pleural mesothelioma [J]. Respir Med，2011，105（1）：137-142.